Advancing a Potent Inhibitor of SARS-CoV-2 3CL Protease into Clinical Trials
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:1 publications
Grant number: 172645
Grant search
Key facts
Disease
COVID-19Start & end year
20202020Known Financial Commitments (USD)
$678,177Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
PendingResearch Location
CanadaLead Research Institution
University of Alberta Medical Microbiology and ImmunologyResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Phase 1 clinical trial
Special Interest Tags
N/A
Study Subject
Clinical
Clinical Trial Details
Clinical Trial, Phase I
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The coronavirus, SARS-CoV-2, has caused COVID-19, a disease that is currently pandemic. The drug GC376 targets an enzyme in the virus that stops its replication. This drug has been used successfully to treat a fatal disease in cats known as Feline Infectious Peritonitis (FIP). FIP is caused by a coronavirus similar to the virus causing COVID-19. This study will move GC376 into phase I human trials on the path to bringing this compound to the benefit of patients with COVID-19.
Publicationslinked via Europe PMC
Last Updated:3 days ago
View all publications at Europe PMC